Research
&
Methodology
Research and Methodology of CMT-MOD Study:
Innovative Biomarker Discovery for Early CMT1A Detection
The CMT-MOD project employs multi-omic techniques, including MRI to identify novel biomarkers for Charcot-Marie-Tooth 1A (CMT1A). Using transcriptomics, proteomics, and advanced machine learning models, this research integrates data from blood, skin, and nerve samples in both animal models and young patients. With a focus on early detection, the methodology bridges experimental findings and clinical applications, aiming to refine diagnosis and enable personalized treatment strategies for children and adolescents with CMT1A.
Key highlights include:
Multi-omic profiling of CMT1A biomarkers.
Integration of advanced bioinformatics tools.
Longitudinal studies on pediatric and adolescent cohorts.
Summary of the Study:
Introduction
The CMT-MOD study investigates early biomarkers in Charcot-Marie-Tooth Disease Type 1A (CMT1A) using advanced methodologies. By combining clinical assessments, MRI analyses, and biomarker identification, the study aims to improve diagnostics and treatment monitoring for young patients. Recruitment will involve 70 CMT1A patients and 40 healthy controls, focusing on individuals aged 10 to 30 years.
Research Objectives
Discovering Early Indicators with Integrated Multi-Omic Analysis:
Using animal models (CMT1A rats), we analyze blood, skin, and nerve samples to uncover early signs of disease severity.
Advanced bioinformatics tools are then used to piece together insights from various biological datasets.
Biomarker Identification in Patients:
We study unique markers from blood tests and MRI scans in young CMT1A patients that could help diagnose and predict the disease.
Optional skin samples provide additional information for identifying these markers.
Machine Learning Integration:
We’re building a machine learning system to combine these findings with patient data.
This system aims to accurately predict how the disease might progress and its severity.
Study Methodology
Clinical Assessment
Patients will undergo comprehensive evaluations at baseline (T1), a mid-point telephone follow-up (T2 at 6 months), and a final visit (T3 at 12 months):
Clinical Measures: CMT Examination Score (CMTES-R), Functional Outcome Measure (CMT-FOM), and Quality of Life (pCMT-QoL).
Patient-Reported Outcomes: Visual Analog Scale (VAS) for pain, fatigue, and cramps; WALK-12 questionnaire; Patient Global Impression of Change (PGI-c).
Electrophysiological Testing: Nerve conduction studies to assess nerve function.
Sample Collection: Blood for transcriptomic and proteomic profiling at T1 and T3. Optional skin biopsies may be conducted.
MRI Biomarker Analysis
Quantitative MRI (qMRI) will be performed to identify muscle and nerve abnormalities in:
Foot and Lower Leg: Measure fat infiltration, muscle volume, and tibial nerve diameter.
Key Metrics: Fat fraction, T2 relaxation time, and magnetization transfer ratio.
MRI data will be processed centrally to ensure consistency.
Biomarker Discovery
Animal Model Analysis:
Utilize blood, skin, and sciatic nerve samples from CMT1A rats to explore disease mechanisms and identify biomarkers.
Patient Sample Analysis:
Perform RNA sequencing and proteomics to identify changes in gene and protein expression associated with disease severity.
Validate findings across patient cohorts using advanced statistical methods.
Machine Learning Applications:
Combine data from clinical assessments, qMRI, and biomarker profiles to create diagnostic and prognostic models.
Employ algorithms such as random forests and support vector machines for accurate predictions.
Ethical Considerations and Safety
Data pseudonymization ensures participant confidentiality.
A Data Safety Monitoring Board (DSMB) oversees safety and study quality.
Ethical approvals will be obtained in compliance with German and French regulations.
Impact
The study aims to:
Identify minimally invasive, cost-effective biomarkers for early diagnosis and monitoring.
Advance understanding of CMT1A disease mechanisms.
Lay the groundwork for targeted therapies in children and young adults.
By integrating advanced techniques and international expertise, the CMT-MOD study aspires to bring transformative insights and hope to those affected by CMT1A.
©Copyright. All rights reserved.
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.